Developing costimulatory molecules for immunotherapy of diseases

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles an.

Front Cover -- Developing Costimulatory Molecules for Immunotherapy of Diseases -- Copyright Page -- Dedication -- Contents -- About the Editor -- Preface -- Acknowledgments -- 1 Introduction to Costimulation and Costimulatory Molecules -- Introduction -- Costimulatory Molecules -- Two-Signal Model of T-cell Activation -- The B7 Family of Costimulatory Ligands -- CD80 Costimulatory Molecule -- CD86 Costimulatory Molecule -- CD80 and CD86 Expression Kinetics -- CD80 and CD86 Binding Kinetics to CD28 and CTLA-4

Different Oligomeric States of CD80 and CD86 -- PD-L1/B7-H1 Costimulatory Molecule -- B7-H2/B7RP-1/LICOS Costimulatory Molecule -- B7-DC/PD-L2 Costimulatory Molecule -- B7-H3 Costimulatory Molecule -- B7-H4 or B7x/B7S1 Costimulatory Molecule -- CD28 Molecule -- CTLA-4 Molecule -- ICOS Molecule -- The Programmed Death-1 -- CD40 Costimulatory Molecule -- CD40L/CD154 Costimulatory Molecule -- Pathways in the TNFR/TNF Family -- 4-1BB/4-1BBL -- OX40/OX40L -- HVEM/LIGHT -- ICOS, GITR, and CD27/CD70 -- Summary -- References

2 Concept of Reverse Costimulation and Its Role in Diseases -- Introduction -- Concept of Bidirectional Costimulation -- Reverse Costimulation of APCs -- Role …